Patent: 8,258,263
✉ Email this page to a colleague
Summary for Patent: 8,258,263
| Title: | Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities |
| Abstract: | Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-.alpha.) or interferon beta (IFN-.beta.). |
| Inventor(s): | Morrison; Sherie L. (Los Angeles, CA), Huang; Tzu-Hsuan (Houston, TX), Xuan; Caiyun (Los Angeles, CA) |
| Assignee: | The Regents of the University of California (Oakland, CA) |
| Application Number: | 12/650,329 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,258,263
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2027-09-21 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2027-09-21 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2027-09-21 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2027-09-21 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
